Insights/Case studies/Newsroom/CareersCareersCareersPartnersConsultantsTechnology innovationCorporateEarly careersSearch Jobs/About us/Contact us Global locations

  • Phone
  • Contact us
  • Locations
  • Search
  • Menu


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Email this article
View or print a PDF of this page

Exacsys™ - helping improve the self-monitoring of blood glucose


PA creates and develops its own IP. The latest example is Exacsys™, a PA venture company, which is helping improve the accuracy of self-monitoring of blood glucose (SMBG) systems for people with diabetes. Diabetes affects over 350 million people around the world and SMBG systems help them manage their condition. 

The accuracy of current systems, however, has been called into question by patients as well as clinicians. Exacsys aims to substantially improve the self-monitoring of blood glucose, providing greater confidence in results and clinical management decisions. 

Exacsys™ has demonstrated a 'proof of concept' system and is developing the technology further to take it to market.

To find out more about our groundbreaking product development, please contact us now.

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.